Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neutropenia 1Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1362Gemcitabine 1235Bevacizumab 1226Paclitaxel 1214Radiotherapy 1176Docetaxel 1080pembrolizumab 1029Oxaliplatin 936Capecitabine 902Fluorouracil 833Rituximab 729Doxorubicin 684Nivolumab 679Dexamethasone 667Etoposide 660Irinotecan 622Leucovorin 576Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 470Cytarabine 467Magnetic Resonance Spectroscopy 461Filgrastim 446Prednisone 433Specimen Handling 411Lenalidomide 410Vincristine 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Maxy G34 × Clear all
NCT00501332 2007-12-24

Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy

Maxygen Holdings Ltd.

Phase 2 Unknown
30 enrolled
Breast

Breast Neoplasms, Neoplasms, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡